Abstract: A compound that has affinity with amyloid, exhibits sufficiently rapid clearance from normal tissues, and is suppressed in toxicity such as mutagenicity is provided, which is represented by the following formula (1): or a salt thereof, wherein R1 is a group selected from hydrogen, hydroxyl group, carboxyl group, sulfate group, amino group, nitro group, cyano group, an alkyl substituent with one to 4 carbon atoms or an alkoxy substituent with one to 4 carbon atoms; R2 is a radioactive halogen substituent; and m is an integer of 0 to 2, and a low-toxic diagnostic agent for Alzheimer's disease comprising a compound represented by the above formula or a salt thereof is also provided.

Abstract: A composition comprising a radioactive fluorine-labeled amino acid compound, which is reduced in radiolysis, is provided. A composition is produced by mixing the radioactive fluorine-labeled amino acid compound with a sugar lactone in an amount effective to prevent the radiolysis As the sugar lactone, one selected from the group consisting of ascorbic acid and glucono-?-lactone can preferably be used. The sugar lactone is preferably one selected from the compounds that are acceptable as pharmaceutical additives. The composition preferably contains the sugar lactone in an amount not less than 0.5 ?mol/mL and not more than an amount acceptable for pharmaceutical additives. Preferably, the composition is prepared to have a radioactive concentration in use of 25-125 MBq/mL.

Abstract: A composition including a radioactive fluorine-labeled amino acid compound is provided, which can be prevented from radiolysis. Disclosed is a composition which includes a solution containing a radioactive fluorine-labeled amino acid compound as an effective ingredient, in which the pH value of the solution is kept at 2.0-5.9, more preferably 2.0-4.9 in order to inhibit radiolysis. Also, it is possible to further inhibit radiolysis by adding thereto a pharmaceutical additive capable of inhibiting radiolysis, such as a sugar, a sugar alcohol and a sugar lactone, whilst the pH is kept at 2.0-5.9.

Abstract: A process is provided for producing a labeled precursor which is useful for production of a radioactive fluorine-labeled amino acid compound. In the reaction step for introducing a leaving group to a mixture of syn-form and anti-form of FACBC, a base is allowed to present in the reaction system to produce a syn-leaving group adduct, which is unreactive with the base and is highly stable, and an anti-leaving group adduct which can react with the base to form a water-soluble compound. By employing a purification method utilizing such a difference in solubility, the syn-leaving group adduct can be separated selectively. The base may be a linear- or branched-chain primary to tertiary alkylamine having 1 to 10 carbon atoms, a nitrogen-containing heterocyclic compound with 2 to 20 carbon atoms, and a nitrogen-containing hetero aromatic compound with 2 to 20 carbon atoms.

Abstract: A catcher frame apparatus is provided including a catcher frame and a catcher roller mounted to the front lower end of a catcher supporting unit of the catcher frame along the direction of the width of a machine body. The catcher frame is connected to the machine body so as to be capable of rotating about an axis of rotation extending along the direction of the width of the machine body, and the catcher supporting unit of the catcher frame is arranged in front of a lawn mowing unit, so that substantially the entire weight of lawn chips stored in a grass catcher supported by the catcher supporting unit is applied to the catcher roller.

Abstract: Oxidized proteins, which have undergone oxidative modifications, are labeled with labeling reagents and quantified by mass spectrometry. In this process, a first labeling reagent, which is capable of reacting with the oxidized proteins, and a second labeling reagent, which has the same chemical structure as the first labeling reagent and in which at least part of the component atoms is substituted by an isotope of the atom concerned, are employed as the labeling reagents. The oxidized proteins labeled with the first labeling reagent and the oxidized proteins labeled with the second labeling reagent are mixed together and subjected to mass spectrometry, with mixing ratios varied. As the labeling reagents, are raised here 2,4-dinitrophenylhydrazine and 2,4-dinitrophenylhydrazine in which a carbon atom on the phenyl group has been substituted by a stable isotope (13C), for example.

Abstract: A process is provided for producing [18F]FACBC, which can reduce the production amount of impurities.

Abstract: It is intended to provide a labeling precursor compound used for selectively producing radioactive halogen-substituted syn-1-amino-3-cyclobutane-carboxylic acids, and to provide a process for producing a radioactive halogen-substituted syn-1-amino-3-cyclobutane-carboxylic acid using the labeling precursor compound. A labeling precursor is used in which a phthalimide group is used as a protective group for protecting the amino group. The syn-form of the radioactive halogen-substituted 1-amino-3-cyclobutane-carboxylic acid can be selectively produced by labeling the labeling precursor with a radioactive halogen followed by deprotecting.

Abstract: There are provided a catcher frame apparatus including a catcher frame and a catcher roller mounted to the front lower end of a catcher supporting unit of the catcher frame along the direction of the width of a machine body. The catcher frame is connected to the machine body so as to be capable of rotating about an axis of rotation extending along the direction of the width of the machine body, and the catcher supporting unit of the catcher frame is arranged in front of a lawn mowing unit, so that substantially the entire weight of lawn chips stored in a grass catcher supported by the catcher supporting unit is applied to the catcher roller.

Abstract: It is intended to provide a novel amino acid organic compound which can be used as a labeling precursor compound for radioactive halogen-labeled amino acid compounds including [18F]FACBC, and which prevents methanol from remaining in the radioactive halogen-labeled amino acid compounds produced therefrom. The novel amino acid organic compound is a compound represented by the following formula: wherein n is an integer of 0 or of 1 to 4; R1 is an ethyl, 1-propyl or isopropyl substituent; X is a halogen substituent or a group represented by —OR2; R2 is a straight-chain or branched-chain haloalkylsulfonic acid substituent with one to 10 carbon atoms, trialkylstannyl substituent with 3 to 12 carbon atoms, fluorosulfonic acid substituent or aromatic sulfonic acid substituent; and R3 is a protective group.

Abstract: A fastener wherein right and left side edge portions can be engaged using a magnetic force, and which can be applied preferably for plastic article such as clothes and further prevented from being opened carelessly even if a lateral pulling force is applied when right and left elements are engaged.

Abstract: A walk-behind lawn mower in a form that a handle arm is integrally provided toward an obliquely upper back in a rear of a machine, and a loop handle is provided at a rear end of the relevant handle arm with slightly tilting forward, and a driver performs drive operation while walking following the machine that travels by itself at a back of the machine, includes a throttle lever, the throttle lever being able to be drawn together with the handle by being operated by either of right and left hands grasping the handle, in addition, engine rotation frequency being able to be controlled using the amount of drawing, wherein the throttle lever is rotatably provided on the handle arm in an obliquely lower front or obliquely upper back of the handle.

Abstract: There is provided a method of screening a preventive and/or therapeutic substance for diseases in which LPA takes part, characterized in that a compound represented by any of formula (I), (II) and (III): [wherein the meaning of characters are described in the description] is used. The compounds obtained by the screening method or the screening kit of the present invention, their salts, their solvates and prodrugs thereof would modulate the binding of highly active LPA with LPA receptor in human and other mammals, so that they can be used as a preventive and/or therapeutic agent for diseases in which LPA takes part, for example, urinary diseases, central nervous diseases, inflammatory diseases, circulatory diseases, cancer, diabetes, immune system disorders and alimentary diseases.

Abstract: A video processing technique which enables users to effectively watch highlight scenes while listening to audio part thereof in a short period of time is disclosed. Upon input of video data, highlight scene data describing therein a highlight scene(s) in the video data is input or generated. Then, based this highlight scene data, determine a default playback parameter. Control is provided to reproduce the highlight scene(s) of the video data in a way such that when inputting a parameter for determination of a playback scene(s), this input playback parameter is used while giving thereto higher priority than the default playback parameter.

Abstract: An agent which comprises, as an active ingredient, a radiolabeled compound as represented by the following formula or a pharmaceutically acceptable salt thereof: wherein R1 denotes hydrogen, or a linear- or branched-chain alkyl group having 1–8 carbon atoms, R2 denotes hydrogen, hydroxyl or a halogen substituent, R3 denotes hydrogen or fluorine substituent, R4 denotes oxygen, sulfur, or a methylene substituent, and R5 denotes a radioactive halogen substituent. The agent is stable in vivo, and either stays in cells or is incorporated in DNA, thus serving for diagnosis of tissue proliferation activity or treatment of proliferative disease.

Abstract: A motion picture recording/reproducing apparatus for embodying the technique includes, at least, a motion picture data input unit which inputs the motion picture data, a storage unit which stores the motion picture data, a recording unit which stores the motion picture data in the storage unit, a feature generating unit which generates a feature of the motion picture data, a ranking generating unit which provides ranking of scenes in the motion picture data according to their importance levels, a reproduction scene deciding unit which decides a reproduction image for each of the scenes in the motion picture data, and a category acquiring unit which acquires the category of the motion picture data. The ranking generating unit provides ranking of the scenes in the input motion picture data on the basis of the acquired category.

Abstract: A video playback apparatus includes: video data inputting unit; a ranking data inputting/generating unit that inputs or generates ranking data where scenes in video data are ranked according to importance; a playback scene determination parameter inputting unit that inputs parameters when determining scenes to be played back according to importance; a playback scene determining unit that determines playback scenes based on ranking data and playback scene determination parameters; and a display unit that displays playback scenes. A viewing time of video data that the user desires and a maximum time width of each playback scene are inputted to the playback scene determination parameter inputting unit, and the playback scene determining unit cuts scenes so that the playback time of the playback scenes fits the maximum time width, and determines the playback scenes so that the sum of the playback time of the playback scenes fits within the viewing time.

Abstract: An agent which comprises, as an active ingredient, a radiolabeled compound as represented by the following formula or a pharmaceutically acceptable salt thereof: wherein R1 denotes hydrogen, or a linear- or branched-chain alkyl group having 1–8 carbon atoms, R2 denotes hydrogen, hydroxyl or a halogen substituent, R3 denotes hydrogen or fluorine substituent, R4 denotes oxygen, sulfur, or a methylene substituent, and R5 denotes a radioactive halogen substituent. The agent is stable in vivo, and either stays in cells or is incorporated in DNA, thus serving for diagnosis of tissue proliferation activity or treatment of proliferative disease.

Abstract: An agent which comprises, as an active ingredient, a radiolabeled compound as represented by the following formula or a pharmaceutically acceptable salt thereof: wherein R1 denotes hydrogen, or a linear- or branched-chain alkyl group having 1-8 carbon atoms, R2 denotes hydrogen, hydroxyl or a halogen substituent, R3 denotes hydrogen or fluorine substituent, R4 denotes oxygen, sulfur, or a methylene substituent, and R denotes a radioactive halogen substituent. The agent is stable in vivo, and either stays in cells or is incorporated in DNA, thus serving for diagnosis of tissue proliferation activity or treatment of proliferative disease.